Loading…
BioLineRx Ltd.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in BLRX.
▼ -97.7% over 5Y.
today you would have $23.64▼ -97.6%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $2.77 | $8.40 | $62.80 | $23.60 | |
| P/S | 6128.8x | 6128.8x | 388.0x | 14216.2x | — |
| P/B | 631.3x | 397.4x | 834.1x | 5160.5x | 428.4x |
| EPS | $0.00 | -$6.00 | -$36.00 | -$18.00 | |
| Profit margin | -99.58% | -99.58% |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| ADGMAdagio Medical Holdings, Inc. | $0.51 | — | — | — | -657.76% | $11.35M |
| TOVXTheriva Biologics, Inc. | $0.25 | 0.2x | 0.9x | — | -101.87% | $11.25M |
| VTGNVistagen Therapeutics, Inc. | $0.25 | — | 0.5x | — | -166.46% | $11.22M |
| MTVAMetaVia Inc. | $1.70 |
BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Company description provided by Yahoo Finance.
| -31.86% |
| -1262.79% |
| — |
| ROE | -58.79% | -6.46% | -68.50% | -458.40% | -49.08% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 1.6x |
| — |
| -175.68% |
| $11.2M |
| KPRXKiora Pharmaceuticals Inc | $2.62 | — | 0.8x | — | -56.37% | $11.59M |
| SNTISenti Biosciences Holdings, Inc. | $0.38 | — | 4.6x | — | -466.46% | $11.74M |